Introduction
============

According to the 2017 World Population Prospects report by the United Nations, the global increase in life expectancy is contributing to a progressive increase in the proportion of the elderly population ([@B1]). Approximately 5% of all patients with cholecystitis have co-existing common bile duct (CBD) stones; among elderly patients with cholecystitis, this percentage is as high as 10-20% ([@B2]). Owing to the higher prevalence of CBD stones in the elderly population, endoscopic stone removal in elderly patients is likely to increase in the future.

Although endoscopic removal of CBD stones using endoscopic retrograde cholangiopancreatography (ERCP) is an effective procedure, it is associated with a high risk of post-ERCP complications, such as post-ERCP pancreatitis (PEP), cholangitis, bleeding, and perforation, in addition to common endoscopic complications, such as pneumonia ([@B3]), which pose serious problems for elderly patients.

In Japan, an age of ≥75 years is classified as old age, while individuals ≥90 years of age are classified as oldest-old ([@B4]). Previous studies have investigated the efficacy and safety of therapeutic ERCP for elderly patients using a cut-off age of 80-85 years ([@B5]-[@B8]); there have been only a few studies on the efficacy and safety of endoscopic stone removal in elderly patients ≥90 years of age. Previous studies published in 2000 and 2006 showed that there was no significant difference in the incidence of post-ERCP complications between elderly patients ≥90 years of age and elderly patients 70-89 years of age. In elderly patients ≥90 years of age, the rate of complete stone removal was lower, additional ERCP attempts were required to achieve stone clearance, and mechanical lithotripters were used more frequently than in those 70-89 years of age ([@B9],[@B10]).

However, these studies included small populations of elderly patients ≥90 years of age, and endoscopic papillary large balloon dilation (EPLBD) has become increasingly popular following the publication of these reports. We therefore examined the efficacy and safety of endoscopic stone removal in a large cohort of elderly patients ≥90 years of age and compared their outcomes with those observed in elderly patients 75-89.

Materials and Methods
=====================

Patient selection and study design
----------------------------------

Medical records pertaining to patients who had undergone therapeutic ERCP for choledocholithiasis at three institutions in Japan between 2012 and March 2018 were retrospectively reviewed. The inclusion criteria were as follows: (1) elderly patients ≥75 years of age with choledocholithiasis; (2) patients with native papilla who underwent endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), or EPLBD; and (3) patients with a normal gastrointestinal tract or Billroth I reconstruction. The exclusion criteria were as follows: (1) patients ≤74 years of age; (2) history of EST, EPBD, or EPLBD; and (3) history of Billroth II or Roux-en-Y reconstruction. A total of 695 elderly patients ≥75 years of age (569 elderly patients 75-89 years of age and 126 elderly patients ≥90 years of age) met the study selection criteria and were included in this study ([Figure](#g001){ref-type="fig"}).

![Flowchart of enrolled patients. EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilation, EPLBD: endoscopic papillary large balloon dilation](1349-7235-58-2125-g001){#g001}

This study was approved by the Institutional Review Boards of each of the participating institutions. Informed consent was obtained from all patients prior to their enrollment.

Outcomes
--------

The primary outcome of this study was the incidence of post-ERCP complications during hospitalization. Secondary outcomes were the frequency of mechanical lithotripter use, the number of successful procedures (complete stone removal or permanent biliary stent placement), and the number of ERCP sessions associated with a successful procedure.

Study definitions
-----------------

### •Trainee endoscopists

Trainee endoscopists were defined as endoscopists who had performed \<200 ERCP procedures or who could perform only procedures equivalent to Grade 1 with or without assistance, according to the ERCP core curriculum published in 2016 ([@B11]).

### •Post-ERCP complications

Post-ERCP complications were defined as all complications that occurred after the ERCP procedure and during hospitalization. Post-ERCP complications included PEP, bleeding, perforation, acute cholangitis/cholecystitis, pneumonia, and cardiovascular and cerebrovascular events. Acute cholangitis/cholecystitis was diagnosed and graded based on the Tokyo guidelines 2018 ([@B12]). Post-ERCP complications, except for acute cholangitis/cholecystitis, were diagnosed and graded based on a lexicon for endoscopic adverse events ([@B13]).

### •Incomplete stone removal and successful procedure

Incomplete stone removal was defined as cases with successful cannulation wherein complete stone removal could not be achieved (excluding cases with unsuccessful cannulation). A successful procedure was defined as complete stone removal or permanent biliary stent placement in cases with incomplete stone removal.

### •Emergency ERCP

Emergency ERCP was defined as ERCP performed within 24 hours of the choledocholithiasis diagnosis.

### •Severe medical conditions as the reason for incomplete clearance

Severe medical conditions were defined as the reason for incomplete clearance in cases with an unstable cardio-respiratory condition before ERCP or with a high risk of deterioration of the cardio-respiratory condition during or after ERCP.

Diagnostic procedure
--------------------

One or more imaging examinations, including computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasonography (EUS), ultrasonography (US), and cholangiography via percutaneous transhepatic gallbladder drainage tube (PTGBD), were performed for the diagnosis of CBD stones in all patients. In cases not diagnosed by imaging examinations, clinical findings such as abdominal pain, dilated CBD, and/or elevated liver function tests were used to establish the diagnosis. The Tokyo guidelines 2018 were used for the diagnosis and grading of acute cholangitis ([@B12]).

Criteria for performing ERCP for choledocholithiasis at our institutions
------------------------------------------------------------------------

At our institutions, the criteria for ERCP for choledocholithiasis required patient consent for the procedure, including detailed information regarding post-ERCP complications. Patients could not exhibit respiratory or circulatory dysfunction if they were to undergo ERCP.

Therapeutic procedure
---------------------

Twenty-five endoscopists were included in this study. Nine of these 25 were trainee endoscopists. ERCP procedures performed by trainee endoscopists were assisted by experienced endoscopists. Side-viewing duodenoscopes (Olympus JF-260, TJF-260V; Olympus Medical Systems, Tokyo, Japan) were used in all patients. Intravenous midazolam and/or pethidine hydrochloride were administered for sedation. The doses of midazolam and pethidine hydrochloride were determined based on the sedation protocol at our institutions.

In patients 75-89 years of age who weighed \<70 kg, the doses of midazolam and pethidine hydrochloride were 1 mg and 17.5-35 mg, respectively, while the doses in those who weighed ≥70 kg were 2 mg and 17.5-35 mg, respectively. In patients ≥90 years of age, the doses of midazolam and pethidine hydrochloride were 1 mg and 17.5 mg, respectively, regardless of weight. Scopolamine butylbromide or glucagon was used for duodenal relaxation. After biliary cannulation, EST, EPBD, or EPLBD followed by biliary stent placement or stone removal was performed. EPLBD was indicated for patients with large and/or multiple stones, with CBD dilation, which were difficult to remove by either EST or EPBD. One or more devices, including balloon catheter, basket, and/or a mechanical lithotripter, were used to remove the CBD stones. A permanent biliary stent was placed in patients with a poor performance status, severe medical condition, and multiple and/or large stones that were difficult to remove based on the endoscopist\'s decision.

Statistical analyses
--------------------

Between-group differences with respect to the demographic and clinical characteristics, ERCP-related findings and outcomes, the reasons for incomplete stone removal, and complications and severity of ERCP were assessed using the chi-squared test, Fisher\'s exact test, or *t*-test, as appropriate. All statistical analyses were performed using R version 3.5.1 (<http://www.R-project.org>). P values \<0.05 were considered indicative of statistically significant differences.

Results
=======

Demographic and clinical characteristics
----------------------------------------

Demographic and clinical characteristics of the study population are presented in [Table 1](#t001){ref-type="table"}. Compared to patients 75-89 years of age, significantly more elderly patients ≥90 years of age underwent emergency ERCP, had severe acute cholangitis, exhibited a dilated common bile duct (\>10 mm), and had a poor performance status (3 or 4). Although not statistically significant, patients ≥90 years of age were more likely to exhibit large stones (\>10 mm) and multiple large stones, compared with patients 75-89 years of age.

###### 

Demographic and Other Characteristics of the Study Population.

                                                                            Patients aged 75-89 years (n=569)   Patients aged ≥90 years (n=126)                       
  ------------------------------------------------------------------------- ----------------------------------- --------------------------------- ------------ ------ ---------
  Age range (years)                                                         75-89                                                                 90-104              
  Sex (female)                                                              284                                 49.9                              87           69.0   \<0.001
  Emergency ERCP                                                            400                                 70.3                              108          85.7   \<0.001
  Clinical presentation                                                                                                                                               
  Acute cholangitis                                                                                                                                                   
  Mild cholangitis                                                          147                                 25.8                              32           25.4   1.0
  Moderate cholangitis                                                      165                                 29.0                              46           36.5   0.12
  Severe cholangitis                                                        42                                  7.4                               19           15.1   0.010
  Biliary pancreatitis                                                      54                                  9.5                               19           15.1   0.091
  Obstructive jaundice without cholangitis                                  35                                  6.2                               2            1.6    0.065
  Elevated liver test with normal serum bilirubin and without cholangitis   48                                  8.4                               4            3.2    0.065
  asymptomatic CBD stones                                                   78                                  13.7                              4            3.2    0.002
  Chronic concomitant diseases                                                                                                                                        
  Hemodialysis                                                              12                                  2.1                               0            0      0.14
  Cardiovascular disease                                                    101                                 17.8                              24           19.0   0.83
  Cerebrovascular disease                                                   57                                  10.0                              14           11.1   0.84
  Liver cirrhosis                                                           6                                   1.1                               1            0.8    1.0
  Diabetes mellitus                                                         65                                  11.4                              9            7.1    0.21
  ≥2 comorbidities                                                          74                                  13.0                              13           10.3   0.50
  Antithrombotic drugs                                                      197                                 34.6                              33           26.2   0.086
  Peri-ampullary diverticulum                                               175                                 30.8                              46           36.5   0.25
  Diameter of common bile duct \[mean, (range)\], mm                        11.7 (4-30)                                                           13.1(5-25)          \<0.001
  Dilated common bile duct (\>10 mm)                                        334                                 58.7                              92           73.0   0.004
  Number of stones \[mean, (range)\]                                        2.3 (0-20)                                                            2.1 (0-15)          0.57
  Multiple stones                                                           228                                 40.1                              53           42.1   0.75
  Size of stones \[mean, (range)\], mm                                      7.9 (2-25)                                                            9.4 (3-30)          0.077
  Large stone (\>10 mm)                                                     115                                 20.2                              36           28.6   0.052
  Multiple and large stones                                                 67                                  11.8                              23           18.3   0.070
  Gallbladder stones                                                        332                                 58.3                              73           57.9   1.0
  Post-cholecystectomy                                                      62                                  10.9                              15           11.9   0.87
  Performance status (3 or 4)                                               124                                 21.8                              55           43.7   \<0.001

ERCP: endoscopic retrograde cholangiopancreatography, CBD: common bile duct

Diagnostic modality for CBD stones
----------------------------------

The imaging modalities used for the diagnosis of CBD stones were MRCP \[79/695 (11.4%)\], CT \[466/695 (67.1%)\], US \[28/695 (4.0%)\], EUS \[2/695 (0.3%)\], and PTGBD \[2/695 (0.3%)\]. More than 2 modalities were used in 118 (17.0%) patients. CBD stones were detected in 574 of the 695 (82.6%) patients by at least 1 imaging modality; in the remaining 121 patients, a clinical diagnosis of CBD was made. In 628 of the 680 (92.4%) patients who underwent successful cannulation, CBD stones were actually detected during ERCP.

Findings and outcomes of ERCP
-----------------------------

ERCP-related findings and outcomes are presented in [Table 2](#t002){ref-type="table"}. No significant differences were observed between elderly patients 75-89 years of age and elderly patients ≥90 years of age with respect to the proportions of procedures performed by trainee endoscopists, the rate of successful cannulation, pancreatic guidewire-assisted cannulation, pancreatic injections, precut sphincterotomy, EST, EPBD, EPLBD, cannulation time \>10 minutes, prophylactic pancreatic stent placement, or procedure time. Complete stone removal was achieved in 540 of the 569 (94.9%) elderly patients 75-89 years of age and in 102 of the 126 (81.0%) elderly patients ≥90 years of age (p\<0.001). In both groups, a permanent biliary stent was successfully placed in all patients with successful cannulation where complete stone removal could not be achieved. No significant between-group differences were observed regarding the use of a mechanical lithotripter, mean number of ERCP sessions per patient required for a successful procedure, and the mean hospital stay duration.

###### 

ERCP-related Findings and Outcomes in Patients Aged 75-89 and ≥90 Years.

                                                            Patients aged 75-89 years (n=569)   Patients aged ≥90 years (n=126)                        
  --------------------------------------------------------- ----------------------------------- --------------------------------- ------------- ------ ---------
  Successful cannulation                                    556                                 97.7                              124           98.4   1.0
  •Complete stone removal                                   540                                 94.9                              102           81.0   \<0.001
  •Incomplete stone removal                                 16                                  2.8                               22            17.5   \<0.001
  Unsuccessful cannulation                                  13                                  2.3                               2             1.6    1.0
  Trainee endoscopist                                       98                                  17.2                              21            16.7   0.98
  PGW-assist cannulation                                    113                                 19.9                              29            23.0   0.50
  Pancreatic injections                                     286                                 50.3                              66            52.4   0.74
  Precut sphincterotomy                                     31                                  5.4                               6             4.8    0.93
  EST                                                       382                                 67.1                              84            66.7   1.0
  EPBD                                                      76                                  13.4                              16            12.7   0.96
  EPLBD                                                     98                                  17.2                              24            19.0   0.72
  Cannulation time\>10 min                                  171                                 30.1                              37            29.4   0.96
  Mechanical lithotripter                                   113                                 19.9                              26            20.6   0.94
  Permanent biliary stent placement                         16                                  2.8                               22            17.5   \<0.001
  Prophylactic pancreatic stent                             98                                  17.2                              25            19.8   0.57
  Procedure time (SD), min                                  27.6 (15.1)                                                           29.8 (20.0)          0.16
  ERCP attempts for successful procedure \[mean (range)\]   2.0 (1-7)                                                             1.9 (1-6)            0.13
  Hospital stay (mean), days                                13.1                                                                  14.7                 0.081

ERCP: endoscopic retrograde cholangiopancreatography, PGW: pancreatic guide-wire, EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilation, EPLBD: endoscopic papillary large balloon dilation

Reasons for incomplete stone removal
------------------------------------

The reasons for incomplete stone removal are presented in [Table 3](#t003){ref-type="table"}. Among patients with incomplete stone removal, significantly more patients ≥90 years of age were unable to tolerate complete stone removal because of severe medical conditions or a poor performance status or dementia than patients 75-89 years of age.

###### 

The Reasons for Incomplete Stone Removal in Patients Aged 75-89 and ≥90 Years.

                                                            Patients aged 75-89 years (n=556)   Patients aged ≥90 years (n=124)               
  --------------------------------------------------------- ----------------------------------- --------------------------------- ---- ------ ---------
  Severe medical conditions intolerable for stone removal   1                                   0.2                               6    4.8    \<0.001
  Poor performance status or dementia                       12                                  2.2                               14   11.3   \<0.001
  Multiple and large stones                                 3                                   0.5                               2    1.6    0.23

Incidence of post-ERCP complications
------------------------------------

Of the 695 patients, 56 (8.1%) experienced post-ERCP complications during hospitalization, including PEP, cholangitis/cholecystitis, bleeding, perforation, pneumonia, and cardiovascular and cerebrovascular events. The incidence of complications among patients 75-89 years of age and patients ≥90 years of age was 7.7% (44/569) and 9.5% (12/126), respectively. There were no significant differences in the incidences of post-ERCP complications between patients 75-89 years of age and patients ≥90 years of age ([Table 4](#t004){ref-type="table"}).

###### 

Incidence of Complications Related to ERCP in Patients Aged 75-89 and ≥90 Years.

                                    Patients aged 75-89 years (n=569)   Patients aged ≥90 years (n=126)             
  --------------------------------- ----------------------------------- --------------------------------- --- ----- -------
  Post-ERCP pancreatitis            21                                  3.7                               2   1.6   0.41
  Acute cholangitis/cholecystitis   11                                  1.9                               2   1.6   1.0
  Bleeding                          4                                   0.7                               3   2.4   0.12
  Perforation                       2                                   0.4                               0   0     1.0
  Pneumonia                         3                                   0.5                               3   2.4   0.076
  Heart failure                     1                                   0.2                               1   0.8   0.33
  Complete atrioventricular block   1                                   0.2                               0   0     1.0
  Cerebral infarction               0                                   0                                 1   0.8   0.18
  Respiratory dysfunction           1                                   0.2                               0   0     1.0

ERCP: endoscopic retrograde cholangiopancreatography

Severity of post-ERCP complications and mortality
-------------------------------------------------

The severity of post-ERCP complications and mortality rates are shown in [Table 5](#t005){ref-type="table"}. There were no significant between-group differences with respect to the severity of post-ERCP complications. The overall mortality rate in our study population was 0.14% (1/695).

###### 

Severity of Post-ERCP Complications in Patients Aged 75-89 and ≥90 Years.

                       Patients aged 75-89 years (n=44)   Patients aged ≥90 years (n=12)              
  -------------------- ---------------------------------- -------------------------------- --- ------ ------
  Mild                 23                                 52.3                             5   41.7   0.74
  Moderate to severe   20                                 45.5                             7   58.3   0.64
  Death                1                                  2.3                              0   0      1.0

ERCP: endoscopic retrograde cholangiopancreatography

Discussion
==========

In the present retrospective study, we compared the safety and efficacy of endoscopic stone removal between elderly patients ≥90 years of age and elderly patients 75-89 years of age. No significant between-group differences were observed with respect to the incidence of post-ERCP complications. Although there was no significant between-group difference with respect to the rate of use of mechanical lithotripter, the rate of complete stone removal in elderly patients ≥90 years of age was significantly lower than that in elderly patients 75-89 years of age.

Several studies have assessed the safety and efficacy of endoscopic removal of CBD stones in elderly patients using the cut-off age of 80-85 years. The results showed that the safety and efficacy of endoscopic stone removal in elderly patients is comparable to that in younger patients ([@B5]-[@B8]). In Japan, patients ≥90 years of age are defined as the oldest-old patients ([@B4]), and a few studies with small sample sizes have assessed the efficacy and safety of stone removal using ERCP in this population. For example, a study found no significant difference in the incidence of post-ERCP complications between elderly patients ≥90 years of age (n=22) and those 70-89 years of age (n=381) \[5% (1/22) vs. 7% (26/381), respectively\]. However, the rate of duct clearance was lower in elderly patients ≥90 years of age than in those 70-89 years of age (86% vs. 95%, respectively) ([@B9]). Another study that included 63 patients ≥90 years of age with pancreatobiliary diseases (including 51 with CBD stones) found no significant difference in the rate of post-ERCP complications between patients ≥90 years of age and those 70-89 years of age \[6.3% (4/63) vs. 8.3% (29/350), respectively\]. However, the number of ERCP attempts for stone clearance was higher, and the use of mechanical lithotripter was more frequent among patients ≥90 years of age than in those 70-89 years of age ([@B10]).

In the present study, there was no significant difference in the incidence of post-ERCP complications between patients 75-89 years of age and those ≥90 years of age (7.7% and 9.5%, respectively), and the incidence of moderate-to-severe complications was also comparable between the groups (45.5% and 58.3%, respectively). The reasons for the comparable incidence of post-ERCP complications and complication severity in the two patient groups might be patient selection and the selection of appropriate endoscopic strategies. At our institutions, patients who met the criteria for ERCP for choledocholithiasis underwent ERCP. Severe cholangitis was more frequently observed in patients ≥90 years of age than in those 75-89 years of age. Patients who were unable to tolerate ERCP were treated by alternative methods, such as antibiotics and percutaneous biliary drainage. Alternative methods were therefore more frequently used in patients ≥90 years of age than in those 75-89 years of age in the present study. Furthermore, permanent stent placement was performed in high-risk patients with a poor performance status or dementia, severe medical conditions, or large and/or multiple stones that were difficult to remove, based on the endoscopist\'s decision. Therefore, when performing ERCP, especially in elderly patients ≥90 years of age, appropriate patient selection and appropriate selection of endoscopic strategies is important.

Although a previous report showed that use of a mechanical lithotripter was more frequent in patients ≥90 years of age ([@B9],[@B10]), no significant between-group difference was observed in the present study. This might be because patients ≥90 years of age with large and/or multiple stones were treated with EPLBD in our study. EPLBD, first reported in 2003, is effective for removing multiple and large CBD stones that are difficult to remove using EPBD or EST alone ([@B14]). In previous studies, stone clearance rates for large stones (\>12-15 mm) without the use of the mechanical lithotripter were 89-99% in patients treated with EPLBD ([@B14]-[@B16]). In the present study, EPLBD was performed in patients with multiple and/or large stones. Patients ≥90 years of age were more likely than those 75-89 years of age to exhibit multiple and/or large stones, although this difference was not statistically significant. This may explain the lack of any significant between-group differences in the frequency of mechanical lithotripter use in the present study.

In the present study, elderly patients ≥90 years of age had a more severe medical condition, poorer performance status, and larger stones than those 75-89 years of age; therefore, the rate of stone clearance was significantly lower than in patients 75-89 years of age (81.0% vs. 94.9%, respectively). These findings are in agreement with earlier reports ([@B9]). A previous report showed that biliary stent placement for two months resulted in partial or complete resolution of large or multiple stones without any complications ([@B17]). For patients in whom complete stone removal is difficult to achieve due to large or multiple stones, regardless of the use of mechanical lithotripter or EPLBD, biliary stent placement at the initial ERCP and subsequent stone removal after two months may be an effective strategy. Long-term biliary stent placement is another alternative strategy for elderly patients with unsuccessful stone clearance. In a prospective study, the patency rates of plastic biliary stent for choledocholithiasis at 6, 12, and 24 months were 94%, 79%, and 58%, respectively ([@B18]). In a systematic review, the mean incidence rates of late complications, biliary-related mortality, and non-biliary-related mortality were 23%, 3.3%, and 20.5%, respectively ([@B19]). Long-term biliary stent placement and close follow-up to detect late complications, such as stent obstruction, are viable options for elderly patients with a poor performance status, severe medical conditions, and multiple and/or large stones.

Appropriate sedation is essential for the success of ERCP procedures. However, sedation can cause oxygen desaturation and/or hypotension. Airway obstruction and respiratory depression have been shown to be the most critical risk factors for mortality associated with endoscopic procedures performed under sedation. The incidence rates outside the operating room were two times higher than inside the operating room ([@B20]). In the present study, there were no significant between-group differences in cardio-respiratory complications, possibly because the dose of medication for sedation was determined by the patient\'s age and weight, based on our institutions\' protocols. However, one of our patients discontinued ERCP after EST because of oxygen desaturation caused by sedation. Fortunately, this patient underwent complete stone removal a few days later. ERCP should be carried out under careful vital sign monitoring, especially in elderly patients.

Although the incidence of post-ERCP complications in patients ≥90 years of age was comparable with that in patients 75-89 years of age in this study, a previous study that examined the risk factors for complications of ERCP among patients ≥85 years of age found that only age ≥90 years was a significant risk factor for therapeutic ERCP ([@B21]). Another study showed that elderly patients ≥75 years of age tended to experience more severe complications during endoscopic stone removal than patients \<75 years of age ([@B22]). Therefore, detailed counseling of elderly patients and their caregivers about the risks of post-ERCP complications is imperative prior to performing ERCP.

Several limitations associated with the present study warrant mention. First, the present study was a retrospective study. Second, one of the participating institutions suffered extensive damage during the Kumamoto earthquake in April 2016. Owing to the disruption caused by the earthquake, the data obtained from that institution pertained only to a 4-year period (April 2012 to April 2016). Third, only patients who met the criteria for ERCP for choledocholithiasis at our institutions were analyzed. We did not determine the proportion of elderly patients 75-89 years of age and ≥90 years of age who were treated by alternative methods (without ERCP), such as antibiotics and percutaneous biliary drainage. Furthermore, permanent stent placement was performed in patients with a poor performance status or dementia, severe medical conditions, or large and/or multiple stones that were difficult to remove, based on the endoscopist\'s decision. Therefore, because our study population was defined by our institutions\' criteria and our endoscopists\' decisions, a selection bias likely exists. Fourth, the long-term outcomes of ERCP in elderly patients ≥90 years of age are unclear because the primary outcome of this study was post-ERCP complications during hospitalization.

In conclusion, we found that the incidence of post-ERCP complications during hospitalization in elderly patients ≥90 years of age was similar to that in elderly patients 75-89 years of age. Although the complete stone removal rate was lower in elderly patients ≥90 years of age than in those 75-89 years of age, biliary stent placement was successful in all patients with incomplete stone removal. Among elderly patients with choledocholithiasis ≥90 years of age, ERCP is a safe and effective procedure; however, when performing ERCP in very elderly patients, endoscopists should consider the risks of ERCP based on each patient\'s medical condition and background and select the appropriate strategy for the patients.
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